Dr. Reddy’s Laboratories’ and its subsidiary, Promius Pharma, LLC has filed three New Drug Applications (NDAs) with the US Food and Drug Administration (USFDA). The three NDAs are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in dermatology and neurology.
Of the three, two are related to dermatology (skincare) applications and one is a corticosteroid. The products upon approval will be commercialized by Promius Pharma.
Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
